Bavarian Nordic EVP on Covid-19 vaccine: "We couldn't have wished for better data"

On Sunday, Bavarian Nordic unveiled data from its phase II study of its Covid-19 vaccine, ABNCoV2. According to Bavarian Nordic's EVP & CIO, the data was the best-case scenario.
Photo: PR / Bavarian Nordic
Photo: PR / Bavarian Nordic
by marketwire, translated by daniel pedersen

Phase II data from Bavarian Nordic's Covid-19 vaccine, ABNCoV2, compares well with known mRNA vaccines from Pfizer/Biontech and US-based Moderna, Executive Vice President and Chief Financial Officer Henrik Juuel tells MarketWire in an interview.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading